Trial Profile
A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Odronextamab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms CLIO-1
- Sponsors Regeneron Pharmaceuticals
- 15 Mar 2024 Status changed from active, no longer recruiting to recruiting.
- 13 Jan 2024 This trial has been Completed in Germany, according to European Clinical Trials Database record.
- 13 Jan 2024 This trial has been Completed in Germany, according to European Clinical Trials Database record.